South Africa has requested the Serum Institute of India to take again the a million COVID-19 vaccine doses the corporate had despatched in early February, The Financial Occasions reported on Tuesday, per week after the nation mentioned it’s going to placed on maintain use of AstraZeneca’s shot in its vaccination program.
Serum Institute of India, which is producing AstraZeneca’s shot, has emerged as a key vaccine provider.
A million doses of the COVID-19 vaccine landed in South Africa final week and one other 500,000 had been because of arrive within the subsequent few weeks.
The corporate didn’t instantly reply to a Reuters request for remark.
South Africa’s well being minister has mentioned the federal government might promote doses of AstraZeneca’s vaccine, after the nation paused its rollout following a small scientific trial that confirmed it provided minimal safety towards gentle to average sickness from the 501Y.V2 coronavirus variant dominant within the nation.
AstraZeneca has mentioned its vaccine appeared to supply solely restricted safety towards gentle illness brought on by the South African variant, primarily based on information from a examine by South Africa’s College of the Witwatersrand and Oxford College.
The African nation, which is but to launch its COVID-19 vaccination program, has determined to begin vaccinating well being employees with Johnson & Johnson’s vaccine within the type of an “implementation examine” with researchers.
The Financial Occasions report additionally comes because the World Well being Group on Monday listed the AstraZeneca/Oxford COVID-19 vaccine for emergency use.
(Aside from the headline, this story has not been edited by NDTV employees and is revealed from a syndicated feed.)